ICU Medical (NASDAQ:ICUI) Director David Greenberg Sells 883 Shares of Company Stock

ICU Medical logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Director David Greenberg sold 883 ICU Medical shares for about $155,514, reducing his holdings by 8.75% to 9,214 shares.
  • ICU Medical’s latest quarterly results beat estimates: EPS was $2.44 versus $2.14 expected, while revenue of $556.2 million exceeded forecasts and rose 4.4% year over year.
  • Analysts have a consensus “Moderate Buy” rating and an average price target of $195.20; 96.1% of the company’s shares are held by institutional investors.
  • Five stocks to consider instead of ICU Medical.

ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) Director David Greenberg sold 883 shares of ICU Medical stock in a transaction dated Friday, November 20th. The stock was sold at an average price of $176.12, for a total value of $155,513.96. Following the completion of the sale, the director owned 9,214 shares in the company, valued at approximately $1,622,769.68. The trade was a 8.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

ICU Medical Price Performance

NASDAQ:ICUI traded down $3.24 during trading hours on Friday, hitting $172.52. 223,433 shares of the stock were exchanged, compared to its average volume of 282,416. The firm's fifty day moving average price is $165.05 and its 200 day moving average price is $150.47. ICU Medical, Inc. has a 52-week low of $113.37 and a 52-week high of $192.85. The company has a market cap of $4.31 billion, a P/E ratio of 72.18, a P/E/G ratio of 2.19 and a beta of 0.88. The company has a current ratio of 2.37, a quick ratio of 1.19 and a debt-to-equity ratio of 0.52.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its earnings results on Thursday, November 5th. The medical instruments supplier reported $2.44 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.30. ICU Medical had a return on equity of 8.40% and a net margin of 2.76%. The business had revenue of $556.22 million for the quarter, compared to the consensus estimate of $552.03 million. During the same quarter last year, the business posted $2.03 earnings per share. The business's quarterly revenue was up 4.4% compared to the same quarter last year. As a group, equities research analysts anticipate that ICU Medical, Inc. will post 7.41 EPS for the current fiscal year.

Institutional Investors Weigh In On ICU Medical

Large investors have recently made changes to their positions in the stock. Allworth Financial LP acquired a new stake in shares of ICU Medical in the 2nd quarter worth $26,000. Bessemer Group Inc. boosted its position in shares of ICU Medical by 65.8% during the 3rd quarter. Bessemer Group Inc. now owns 189 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 75 shares during the last quarter. Global Retirement Partners LLC grew its holdings in shares of ICU Medical by 203.4% in the third quarter. Global Retirement Partners LLC now owns 179 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 120 shares during the period. Hantz Financial Services Inc. grew its holdings in shares of ICU Medical by 78.4% in the third quarter. Hantz Financial Services Inc. now owns 239 shares of the medical instruments supplier's stock valued at $38,000 after purchasing an additional 105 shares during the period. Finally, Versant Capital Management Inc grew its holdings in shares of ICU Medical by 26.2% in the third quarter. Versant Capital Management Inc now owns 313 shares of the medical instruments supplier's stock valued at $50,000 after purchasing an additional 65 shares during the period. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ICUI shares. Wall Street Zen upgraded ICU Medical from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 8th. BTIG Research upped their target price on shares of ICU Medical from $170.00 to $200.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Raymond James Financial reiterated a "strong-buy" rating and issued a $200.00 target price on shares of ICU Medical in a research report on Friday, August 7th. Needham & Company LLC increased their target price on shares of ICU Medical from $165.00 to $187.00 and gave the company a "buy" rating in a research report on Friday, August 7th. Finally, KeyCorp raised their price target on shares of ICU Medical from $187.00 to $189.00 and gave the stock an "overweight" rating in a research note on Friday, November 6th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $195.20.

Get Our Latest Report on ICUI

ICU Medical Company Profile

(Get Free Report)

ICU Medical is a medical technology company that develops, manufactures and markets products used in infusion therapy, vascular access and critical care. Its offerings include infusion pumps and related sets and accessories, IV solutions, needlefree connectors, and products designed to help protect healthcare workers when handling hazardous drugs. Founded in 1984, the company expanded its product portfolio through acquisitions, including the infusion systems business of Hospira in 2017 and Smiths Medical in 2022.

See Also

Insider Buying and Selling by Quarter for ICU Medical (NASDAQ:ICUI)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ICU Medical Right Now?

Before you consider ICU Medical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICU Medical wasn't on the list.

While ICU Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines